Shattuck Labs, Inc.·4

May 14, 8:10 PM ET

Neill Andrew R 4

4 · Shattuck Labs, Inc. · Filed May 14, 2026

Research Summary

AI-generated summary of this filing

Updated

Shattuck Labs (STTK) CFO Neill Exercises Warrants, Receives 64,027 Shares

What Happened Neill Andrew R, Chief Financial Officer of Shattuck Labs (STTK), exercised previously held warrants and acquired 64,027 shares of common stock on 2026-05-12. The acquisition was reported as an "A" (award/acquisition) of 64,027 shares at $1.08 per share for a total reported cost of $69,444. The filing also records an "M" (exercise/conversion of a derivative) for 64,027 shares, indicating the underlying warrants were converted/used in the transaction.

Key Details

  • Transaction date: 2026-05-12; Filing date (Accession): 2026-05-14 (filed two days after the transaction).
  • Acquired: 64,027 shares at $1.08/share; total reported purchase amount $69,444.
  • Derivative: 64,027-warrant position was exercised/converted (M code); exercise price shown as N/A in the derivative line because the derivative instrument was disposed (warrant extinguished) in the conversion.
  • Shares owned after transaction: Not disclosed in the provided excerpt.
  • Footnote summary:
    • F1: These shares/warrants trace to a private placement closed Aug 25, 2025; the Reporting Person purchased 64,027 shares and accompanying warrants at a combined price per share+Warrant of $0.8677.
    • F2: The warrants are exercisable until 30 days after certain Phase 1 clinical trial data and Phase 2 design have been publicly announced.

Context

  • This was an exercise/conversion of warrants into common stock (derivative -> shares), not an open-market buy or sale. The warrants extinguished upon conversion; the record shows the CFO ended up with the newly issued common shares.
  • The dollar amount is modest (~$69k). The filing appears timely (reported two days after the trade), and there is no indication of a 10b5-1 plan, tax withholding, or gift involved in the disclosed entries.

Insider Transaction Report

Form 4
Period: 2026-05-12
Neill Andrew R
Chief Financial Officer
Transactions
  • Award

    Common Stock

    2026-05-12$1.08/sh+64,027$69,444292,251 total
  • Exercise/Conversion

    Warrants (Right to Buy)

    [F1][F2]
    2026-05-1264,0270 total
    Exercise: $1.08Common Stock (64,027 underlying)
Footnotes (2)
  • [F1]On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 64,027 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 64,027 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677.
  • [F2]The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly.
Signature
/s/ Andrew R. Neill|2026-05-14

Documents

1 file
  • 4
    ownership.xmlPrimary

    4